环球医疗器械
GMED
76.71
-2.13
-2.70%
环球医疗器械
US · GMED
#1454 按市值排名
上市于 1970
76.71
-2.13
-2.70%
实时 - 追踪5344个代码 - 心跳于35秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 90.23% +0.18pp
- 机构数量
- 692 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund76.89%
Individual/Insider17.18%
Hedge Fund6.25%
Public Company2.63%
Government Pension Fund1.58%
Private Company1.06%
Sovereign Wealth Fund0.85%
Insurance Company0.48%
VC/PE Fund0.20%
主要股东 截至 2026-03-31
David Paul
16.62% · 22.32M 股
BlackRock
8.05% · 10.81M 股
Janus Henderson Group plc
6.11% · 8.20M 股
Vanguard Capital Management, LLC
4.34% · 5.82M 股
Vanguard Portfolio Management, LLC
3.72% · 4.99M 股
Kayne Anderson Rudnick Investment Management, LLC
3.19% · 4.28M 股
Invesco Ltd.
3.03% · 4.07M 股
State Street Global Advisors
2.77% · 3.71M 股
Sculptor Capital Management, Inc.
2.23% · 3.00M 股
J.P. Morgan Asset Management, Inc.
1.93% · 2.59M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 19次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| David Paul | Co-Founder & Executive Chairperson | 16.62% |
| David Davidar | Independent Director | 0.50% |
| Ann Rhoads | Independent Director | 0.03% |
| Daniel Wolterman | Director | 0.02% |
| Leslie Norwalk | Director | 0.01% |
| Robert Douglas | Independent Director | 0.00% |
| John DeFord | Director | -- |
| Stephen Zarrilli | Independent Director | -- |
| James Tobin | Independent Director | -- |
| Daniel Lemaitre | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | James Tobin | Independent Director | Derivative Exercise and Sale | -30,000 | $53.75–74.58 |
| 2026-08-17 | Stephen Zarrilli | Independent Director | Derivative Exercise and Sale | -25,000 | $53.27–87.04 |
| 2026-07-26 | David Davidar | Independent Director | Other Disposition | -2,500 | -- |
| 2026-06-04 | David Davidar | Independent Director | Derivative Exercise and Sale | -25,000 | $26.27–80.76 |
| 2026-06-03 | Ann Rhoads | Independent Director | Derivative Exercise and Retained | +25,000 | $26.27 |
| 2026-04-13 | John DeFord | Director | Intent to Sell (Form 144) | -30,000 | $93.10 |
| 2026-02-24 | Kelly Huller | Senior Vice President | Derivative Exercise and Sale | -20,000 | $43.58–94.50 |
| 2026-02-11 | Kelly Huller | Senior Vice President | Derivative Exercise and Sale | -10,000 | $45.64–87.67 |
| 2026-01-20 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | John DeFord | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Stephen Zarrilli | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | James Tobin | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Paul | Co-Founder & Executive Chairperson | Other Derivative Acquisition | +100,000 | $94.15 |
| 2026-01-20 | Daniel Wolterman | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Robert Douglas | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Davidar | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Leslie Norwalk | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Daniel Lemaitre | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Keith Pfeil | Senior Vice President | Other Derivative Acquisition | +100,000 | $94.15 |
| 2026-01-20 | Kelly Huller | Senior Vice President | Other Derivative Acquisition | +40,000 | $94.15 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
环球医疗器械 讨论区 0 条评论